Optiscan Imaging Limited engages in the development and commercialization of confocal endomicroscopic imaging technologies for medical, translational, and pre-clinical applications in Australia, North America, Europe, and Asia.
+ 3 more risks
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Optiscan Imaging's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OIL's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: OIL underperformed the Australian Medical Equipment industry which returned 30.4% over the past year.
Return vs Market: OIL underperformed the Australian Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is Optiscan Imaging's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIf You Had Bought Optiscan Imaging (ASX:OIL) Stock Five Years Ago, You'd Be Sitting On A 41% Loss, Today
3 months ago | Simply Wall StWhat Kind Of Shareholders Own Optiscan Imaging Limited (ASX:OIL)?
4 months ago | Simply Wall StHealth Check: How Prudently Does Optiscan Imaging (ASX:OIL) Use Debt?
Is Optiscan Imaging undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OIL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OIL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OIL is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: OIL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OIL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OIL is overvalued based on its PB Ratio (4.5x) compared to the AU Medical Equipment industry average (4.2x).
How is Optiscan Imaging forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Optiscan Imaging has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Optiscan Imaging's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Optiscan Imaging competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Optiscan Imaging performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OIL is currently unprofitable.
Growing Profit Margin: OIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OIL is unprofitable, and losses have increased over the past 5 years at a rate of -13.9% per year.
Accelerating Growth: Unable to compare OIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OIL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).
Return on Equity
High ROE: OIL has a negative Return on Equity (-83.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Optiscan Imaging's financial position?
Financial Position Analysis
Short Term Liabilities: OIL's short term assets (A$3.4M) exceed its short term liabilities (A$818.4K).
Long Term Liabilities: OIL's short term assets (A$3.4M) exceed its long term liabilities (A$2.2K).
Debt to Equity History and Analysis
Debt Level: OIL's debt to equity ratio (7.1%) is considered satisfactory.
Reducing Debt: OIL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Inventory Level: OIL has a high level of physical assets or inventory.
Debt Coverage by Assets: OIL's debt is covered by short term assets (assets are 16.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OIL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OIL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.8% each year
What is Optiscan Imaging's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate OIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OIL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OIL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OIL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Optiscan Imaging has no CEO, or we have no data on them.
|Executive Chairman||1.8yrs||AU$517.27k||0.36% A$46.6k|
|Non-Executive Director||2.6yrs||AU$176.13k||3.82% A$493.0k|
|Non-Executive Director||1.8yrs||AU$49.31k||2.29% A$296.0k|
Experienced Board: OIL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Optiscan Imaging Limited's company bio, employee growth, exchange listings and data sources
- Name: Optiscan Imaging Limited
- Ticker: OIL
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$12.900m
- Shares outstanding: 477.78m
- Website: https://www.optiscan.com
- Optiscan Imaging Limited
- 16 Miles Street
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OIL||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Aug 1997|
|OIL||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Aug 1997|
Optiscan Imaging Limited engages in the development and commercialization of confocal endomicroscopic imaging technologies for medical, translational, and pre-clinical applications in Australia, North America, Europe, and Asia. It offers ViewnVivo, a miniaturized fluorescence endomicroscope platform that brings imaging flexibility to preclinical research. The company also provides FIVE2 ViewnVivo system that enables virtual biopsies in living tissue. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 10:36|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.